Press Releases

EHA 2026 | HANSOH PHARMA PRESENTED DATA FROM TWO CLINICALSTUDIES OF HS-10382, A NOVEL BCR::ABL1 ALLOSTERIC INHIBITOR, IN CHRONIC MYELOID LEUKEMIA (CML)

NEW DRUG APPLICATION FOR OLATOREPATIDE INJECTION ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

SID 2026 | HANSOH PHARMA PRESENTED PHASE 1 DATA OF HS-20118 IN HEALTHY ADULTS AND PSORIASIS PATIENTS

AACR 2026 | HANSOH PHARMA PRESENTED RESULTS OF HS-10504 (A NOVEL, POTENT, HIGHLY SELECTIVE, FOURTH-GENERATION EGFR TKI) FROM A FIRST IN HUMAN PHASE 1 STUDY IN PATIENTS WITH ADVANCED NSCLC

AAN 2026 | HANSOH PHARMA PRESENTED PHASE 1B/2 DATA OF HS-10506 (A SELECTIVE OREXIN-2 RECEPTOR ANTAGONIST) IN INSOMNIA

HANSOH PHARMA – XINYUE’S THIRD INDICATION APPROVED FOR MARKETING FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS IN ADULT PATIENTS

ELCC 2026 | HANSOH PHARMA PRESENTED RESULTS OF DALMELITINIB (HS-10241, A HIGHLY SELECTIVE MET-TKI) COMBINED WITH AUMOLERTINIB FROM A PHASE IB STUDY IN PATIENTS WITH MET-AMPLIFIED ADVANCED NSCLC POST EGFR TKI

OLATOREPATIDE (HS-20094) ACHIEVES UP TO 19.3% WEIGHT LOSS AT WEEK 48 IN PHASE 3 STUDY WITH FAVORABLE GASTROINTESTINAL TOLERABILITY